Takashi Higuchi * , † , ‡ , Hiromichi Oshiro * , † , Zhiying Zhang * , † , Kentaro Miyake * , † , Norihiko Sugisawa * , † , Yuki Katsuya * , † , Norio Yamamoto ‡ , Katsuhiro Hayashi ‡ , Hiroaki Kimura ‡ , Shinji Miwa ‡ , Kentaro Igarashi ‡ , Ming Zhao * , Michael Bouvet † , * , Shree Ram Singh § , * , Hiroyuki Tsuchiya ‡ , * , Robert M Hoffman * , † , *
23 February 2019
The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.